• About Us
    • About EirGenix
    • Milestones
    • Vision and Mission
    • Facilities and Capacities
      • Xizhi Facility
      • Zhubei Facility
    • Management Team
    • Videos
    • 360-Degree Virtual Tour
  • News
    • News
    • Events
  • Services
    • Cell Line Development
    • Process Development
    • Analytical & Quality Control
    • cGMP manufacturing–mammalian system
    • cGMP manufacturing–microbial system
    • Antibody-Drug Conjugate
  • Products
    • PRODUCT PIPELINE
    • CRM197 CARRIER PROTEIN
    • COVID-19 ANTIGEN RAPID TEST
  • Investor
    • Financials
      • Monthly Revenue
        • 2023
        • 2022
        • 2021
        • 2020
        • 2019
        • 2018
      • Financial Reports
        • 2022
        • 2021
        • 2020
        • 2019
        • 2018
    • Corporate Governance
      • Corporate Governance
      • Board of Directors
      • Internal Audit
    • Shareholder Services
      • Shareholders' Meeting
      • Investor Conference
      • Dividend Distribution
      • Market Observation Post System
      • Investor Relations & Media Contact
      • Stock Transfer Agent
    • ESG
      • ESG Overview
  • Recruiting
  • Contact Us
| English | 繁體中文
EN
  • EN
  • 繁中
  • LINKEDIN
  • YOUTUBE
  • Home
  • News
  • Events
News
  • News
    • EirGenix rated top 5% Corporate Governance Evaluation at TPEx after second year of the IPO
    • EIRGENIX ACHIEVES THE FIFTH MILESTONE OF ITS TRASTUZUMAB BIOSIMILAR LICENSING AGREEMENT
    • MARKETING AUTHORIZATION APPLICATION (MAA) SUBMITTED FOR EIRGENIX'S TRASTUZUMAB BIOSIMILAR TO EMA
    • BIOLOGICS LICENSE APPLICATION (BLA) SUBMITTED TO U.S FDA FOR EIRGENIX'S TRASTUZUMAB BIOSIMILAR
    • EG12014'S PHASE III CLINICAL TRIAL INTERIM RESULTS PUBLISHED AT SAN ANTONIO BREAST CANCER SYMPOSIUM
    • EirGenix Completed Its NTD 5.03 Billion Private Placement on the Fifteenth of October
    • EIRGENIX ACHIEVES THE FOURTH MILESTONE OF ITS TRASTUZUMAB BIOSIMILAR LICENSING AGREEMENT
    • HONG HAI/FOXCONN FOUNDER TERRY GUO ANNOUNCES INVESTMENT TO ACCELERATE EIRGENIX’S GLOBAL EXPANSION
    • POSITIVE PHASE III CLINICAL RESULTS FOR EIRGENIX'S PROPOSED TRASTUZUMAB BIOSIMILAR
    • EIRGENIXは日本市場を拡大するために、日本の会社と長期供給契約の締結について
    • EIRGENIX COMPLETES NEOADJUVANT TREATMENT AND SURGERY FOR LAST PATIENT IN PHASE III CLINICAL TRIAL
    • VSTRIP® COVID-19 ANTIGEN RAPID TEST VALIDATED AND APPROVED IN INDIA!
    • EIRGENIX ACHIEVES THE THIRD MILESTONE OF ITS TRASTUZUMAB BIOSIMILAR LICENSING AGREEMENT
    • EIRGENIX RECEIVES 2020 BIOPROCESSING EXCELLENCE IN GREATER CHINA REGION AWARD!
    • EIRGENIX ACHIEVES THE SECOND MILESTONE OF ITS BIOSIMILAR TRASTUZUMAB - LICENSING AGREEMENT
    • EIRGENIX RECEIVES APPROVAL FROM JAPAN'S PMDA
    • EIRGENIX'S REVENUE REACHES A RECORD HIGH IN JUNE
    • EIRGENIX COLLECTS ITS INITIAL SIGNING FEE DAYS BEFORE ITS OFFICIAL IPO
    • EIRGENIX INC. ANNOUNCES 3-DAY STOCK OPTION BIDDING AHEAD OF ITS LATE-JUNE IPO
    • EIRGENIX HOLDS ITS PRE-IPO PRESS CONFERENCE
    • EIRGENIX SIGNS TRASTUZUMAB BIOSIMILAR LICENSE AGREEMENT WITH NOVARTIS SANDOZ
    • EIRGENIX AWARDED FOR ITS INNOVATION AT THE NATIONAL INDUSTRIAL INNOVATION AWARDS
    • EIRGENIX, INC. WINS BEST BIOPROCESS EXCELLENCE IN TAIWAN AWARD
    • EIRGENIX, INC. OFFICIALLY OPENS ITS NEW WORLD-CLASS COMMERCIAL MASS PRODUCTION FACILITY
    • EIRGENIX'S PHASE III CLINICAL TRIAL OF EG12014 HAS ENROLLED FIRST PATIENT
    • CANCER THERAPEUTIC DRUG EG12014 IS APPROVED FOR PHASE III CLINICAL TRIAL
    • EIRGENIX IS AWARD TOP 145 OF THE TECHNOLOGY FAST 500 COMPANIES IN ASIA PACIFIC (APAC)
    • EIRGENIX RECEIVED "ASIA'S BEST CMO"
    • EIRGENIX RECEIVED THE ACCREDITATION CERTIFICATE OF FOREIGN DRUG MANUFACTURER FROM JAPAN
    • EIRGENIX HELD THE WHOLE NEW "PROTEIN DRUG COMMERCIAL PRODUCTION PLANT" BEAM-RAISING CEREMONY
    • CANCER THERAPEUTIC DRUG EG12014 PASSED THE DOUBLE-BLINDED PHASE I CLINICAL TRIAL
    • EIRGENIX RECEIVED "GRAND WINNER OF BEST BIOPROCESS EXCELLENCE IN TAIWAN"
    • EIRGENIX HELD THE WHOLE NEW "PROTEIN DRUG COMMERCIAL PRODUCTION PLANT" GROUNDBREAKING CEREMONY
    • 2015 TAIWAN BIO-MEDICAL AND NEW AGRICULTURAL INDUSTRY DRAFT COMPETITION AWARDS CEREMONY
    • EIRGENIX AND FORMOSA LABORATORIES COLLABORATE TO ESTABLISH A PLATFORM FOR ADC CMC INTEGRATION SERVIC
    • EIRGENIX DEVELOPS AND MANUFACTURES BIOLOGICS
  • Events
    • Antibody Therapeutic Conference -November-15,2022
    • EIRGENIX AT CPHI WORLDWIDE 2021 IN Frankfurt, Germany
    • EIRGENIX AT BIO-EUROPE® - October 24–26, 2022
    • EIRGENIX AT BIO ASIA-TAIWAN EXHIBITION - JULY 28-31, 2022
    • EirGenix, Inc. joins the 2022 BIO International Convention in San Diego, CA from June 13 to June 16.
    • EIRGENIX AT THE HEALTHCARE + EXPO TAIWAN - DECEMBER 2-5, 2021
    • EIRGENIX AT BIO ASIA-TAIWAN EXHIBITION - NOVEMBER 4-7, 2021
    • EIRGENIX AT CPHI WORLDWIDE 2021 IN MILAN, ITALY
    • EIRGENIX AT 2020 HEALTHCARE+ EXPO TAIWAN - DECEMBER 3-6-2020
    • 【2020 HEALTHCARE+ EXPO TAIWAN】EIRGENIX INC. - YOUR RELIABLE BIOLOGICS PARTNER!
    • EIRGENIX AT BIO ASIA-TAIWAN CONFERENCE AND EXHIBITION - JULY 22-26, 2020
    • EIRGENIX AT HEALTHCARE + EXPO TAIWAN – DECEMBER 5-8, 2019
    • EIRGENIX AT BIO ASIA-TAIWAN CONFERENCE AND EXHIBITION - JULY 25-28, 2019
    • 2018 BIOLOGICS MANUFACTURING KOREA
    • OUTSTANDING RESULTS FROM 2016 BIO INTERNATIONAL CONVENTION
    • 2015 6TH WORLD ADC SUMMIT SAN DIEGO
    • BIO TAIWAN 2015
    • CPHI JAPAN 2015
    • ANTIBODY DRUGS NOVEL BIOLOGICAL SUMMIT 2015
    • BIOTAIWAN CONVENTION 2014
    • COGRATULATE EIRGENIX' SUCCESSFUL EXHIBITION IN BIOTECH JAPAN 2014!

Events

Antibody Therapeutic Conference -November-15,2022

 2022/11/14

EIRGENIX AT CPHI WORLDWIDE 2021 IN Frankfurt, Germany

 2022/10/17

EIRGENIX AT BIO-EUROPE® - October 24–26, 2022

 2022/10/17

EIRGENIX AT BIO ASIA-TAIWAN EXHIBITION - JULY 28-31, 2022

 2022/07/27
EirGenix, Inc. joins the 2022 BIO International Convention in San Diego, CA from June 13 to June 16.

EirGenix, Inc. joins the 2022 BIO International Convention in San Diego, CA from June 13 to June 16.

 2022/03/25
EIRGENIX AT THE HEALTHCARE + EXPO TAIWAN - DECEMBER 2-5, 2021

EIRGENIX AT THE HEALTHCARE + EXPO TAIWAN - DECEMBER 2-5, 2021

 2021/12/01
EIRGENIX AT BIO ASIA-TAIWAN EXHIBITION - NOVEMBER 4-7, 2021

EIRGENIX AT BIO ASIA-TAIWAN EXHIBITION - NOVEMBER 4-7, 2021

 2021/11/01
EIRGENIX AT CPHI WORLDWIDE 2021 IN MILAN, ITALY

EIRGENIX AT CPHI WORLDWIDE 2021 IN MILAN, ITALY

 2021/10/05
EIRGENIX AT 2020 HEALTHCARE+ EXPO TAIWAN - DECEMBER 3-6-2020

EIRGENIX AT 2020 HEALTHCARE+ EXPO TAIWAN - DECEMBER 3-6-2020

 2020/12/03
【2020 HEALTHCARE+ EXPO TAIWAN】EIRGENIX INC. - YOUR RELIABLE BIOLOGICS PARTNER!

【2020 HEALTHCARE+ EXPO TAIWAN】EIRGENIX INC. - YOUR RELIABLE BIOLOGICS PARTNER!

 2020/09/21
EIRGENIX AT BIO ASIA-TAIWAN CONFERENCE AND EXHIBITION - JULY 22-26, 2020

EIRGENIX AT BIO ASIA-TAIWAN CONFERENCE AND EXHIBITION - JULY 22-26, 2020

 2020/07/20
EIRGENIX AT HEALTHCARE + EXPO TAIWAN – DECEMBER 5-8, 2019

EIRGENIX AT HEALTHCARE + EXPO TAIWAN – DECEMBER 5-8, 2019

 2019/12/05
EIRGENIX AT BIO ASIA-TAIWAN CONFERENCE AND EXHIBITION - JULY 25-28, 2019

EIRGENIX AT BIO ASIA-TAIWAN CONFERENCE AND EXHIBITION - JULY 25-28, 2019

 2019/07/23
2018 BIOLOGICS MANUFACTURING KOREA

2018 BIOLOGICS MANUFACTURING KOREA

 2018/06/01
OUTSTANDING RESULTS FROM 2016 BIO INTERNATIONAL CONVENTION

OUTSTANDING RESULTS FROM 2016 BIO INTERNATIONAL CONVENTION

 2016/06/23
  • 1
  • 2
  • ›
  • Sitemap
  • Privacy Policy
  • EIP
copyright © 2023 EirGenix, Inc. all rights reserved.
EirGenix, Inc.
  • Address No. 101, Lane 169, Kangning St., Xizhi Dist, New Taipei City 22180, Taiwan, R.O.C
  • TEL +886-2-7708-0123
  • FAX +886-2-7708-1666
  • E-mail service@eirgenix.com
  • LINKEDIN
  • YOUTUBE